Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Major, Ajay; Yu, Jovian; Shukla, Navika; Treitman, Rachel; Kamdar, Manali; Haverkos, Bradley M.; Godfrey, James; Babcook, Melissa A.; Voorhees, Timothy J.; Carlson, Sophie G; Gaut, Daria; Oliai, Caspian; Romancik, Jason T.; Winter, Allison M.; Hill, Brian T.; Bansal, Radhika; Villasboas, José C.; Nizamuddin, Imran; Karmali, Reem; Fitzgerald, Lindsey; Stephens, Deborah M.; Pophali, Priyanka A.; Trabolsi, Asaad; Schatz, Jonathan H.; Hu, Marie; Bachanová, Veronika; Slade, Michael; Singh, Nathan; Ahmed, Nausheen; McGuirk, Joseph P.; Bishop, Michael; Riedell, Peter A.; Kline, Justin

doi:10.1182/blood-2022-157829

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11][12][13] A recent abstract showed that patients in relapse after CAR Tcell therapy had low response rate and low median survival after being treated with anti-PD1 treatment. 14 In conclusion, we reported that patients in PR after axicel for DLBCL, with or without subsequent progression, may benefit from nivolumab. This subgroup of patients needs to be further studied before this strategy can be broadly advised.…”

Section: Safety and Efficacy Of Nivolumab In Patients Who Failed To A...mentioning

confidence: 64%

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19‐directed CAR T‐cell therapy in diffuse large B cell lymphoma

et al. 2023

View full text Add to dashboard Cite

Section: Safety and Efficacy Of Nivolumab In Patients Who Failed To A...mentioning

confidence: 64%

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19‐directed CAR T‐cell therapy in diffuse large B cell lymphoma

et al. 2023

View full text Add to dashboard Cite

“…Small case series of ICIs as subsequent treatment after CAR T‐cells 35 and clinical trials combining CAR‐T with ICIs have reported modest clinical efficacy 36,37 . In terms of our ICI cohort, the CR rate was similar to other reports in the same setting (26% vs. 25%) 21 and higher than the large US multicenter study recently published ( N = 96, ORR 19%, CR 10%) 38 . Noteworthy, even though this group had a comparable PFS to the POLA and BsAb patients, OS was significantly shorter.…”

Section: Discussionmentioning

confidence: 92%

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy

Iacoboni,

Iraola‐Truchuelo,

O'Reilly

et al. 2024

HemaSphere

View full text Add to dashboard Cite

Over 60% of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of therapy and information in this setting is scarce and heterogeneous. We analyzed 387 R/R LBCL patients who progressed after CAR T cells from July 2018 until March 2022 in Spain and the United Kingdom. Median overall survival (OS) was 5.3 months, with significant differences according to the interval between infusion and progression (<2 months [1.9 months], 2–6 months [5.2 months], and >6 months [not reached]). After progression, 237 (61%) patients received treatment. Focusing on the first subsequent therapy, overall (complete) response rates were 67% (38%) for polatuzumab–bendamustine–rituximab (POLA), 51% (36%) for bispecific antibodies (BsAb), 45% (35%) for radiotherapy (RT), 33% (26%) for immune checkpoint inhibitors (ICIs), 25% (0%) for lenalidomide (LENA), and 25% (14%) for chemotherapy (CT). In terms of survival, 12‐month progression‐free survival and OS was 36.2% and 51.0% for POLA, 32.0% and 50.1% for BsAb, 30.8% and 37.5% for RT, 29.9% and 27.8% for ICI, 7.3% and 20.8% for LENA, and 6.1% and 18.3% for CT. Thirty‐two (14%) patients received an allogeneic hematopoietic cell transplant with median OS not reached after a median follow‐up of 15.1 months. In conclusion, patients with R/R LBCL who progress within the first 2 months after CAR T‐cell therapy have dismal outcomes. Novel targeted agents, such as polatuzumab and BsAbs, can achieve prolonged survival after CAR T‐cell therapy failure.

show abstract

Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need

et al. 2023

View full text Add to dashboard Cite

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Cited by 4 publications

References 0 publications

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19‐directed CAR T‐cell therapy in diffuse large B cell lymphoma

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19‐directed CAR T‐cell therapy in diffuse large B cell lymphoma

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy

Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need

Contact Info

Product

Resources

About